ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery ...
MaxCyte signed a strategic platform license (SPL) with Walking Fish Therapeutics which focuses on B cell-based therapeutics. Walking Fish obtains non-exclusive clinical and commercial rights to use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results